• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Glialogix, National Multiple Sclerosis Society collaborate

Glialogix, National Multiple Sclerosis Society collaborate

October 2, 2014
CenterWatch Staff

Glialogix, a San Francisco Bay Area-based emerging biopharma company, has entered into a sponsored research agreement with Fast Forward, a nonprofit organization established by the New York-based National Multiple Sclerosis (MS) Society to accelerate the development of treatments for MS. Fast Forward will provide funding for preclinical studies of GLX1112, a first-in-class neuroprotective therapy designed to slow the accumulation of disability in progressive MS.

“The treatment of patients with progressive MS represents a significant unmet medical need. The majority of MS disability occurs in the progressive forms of MS, but drugs that are effective for relapsing MS have shown limited to no efficacy in progressive MS,” said Mark Moore, Ph.D., CEO of Glialogix. “The research funding from Fast Forward validates our therapeutic approach for GLX1112 and will help us advance this investigational drug as a potential breakthrough therapy for the treatment of patients with progressive MS.”

The research to be funded by Fast Forward will include advanced pharmacokinetic testing, preclinical models and further mechanistic studies of GLX1112.

“A unique aspect of our program is that the active pharmaceutical ingredient in GLX1112 already has demonstrated a promising efficacy signal in progressive MS patients,” said Thadd Reeder, Ph.D., chief scientific officer of Glialogix and lead investigator of the GLX1112 preclinical research. “The support of Fast Forward will enable us to build on that signal by moving GLX1112 closer to clinical trials and may contribute to the development of new clinical trial designs in progressive MS.”

“The National MS Society is committed to identifying and helping develop new therapies for people living with multiple sclerosis,” said Bruce Bebo, Ph.D., executive vice president, research at the National MS Society. “Glialogix has an innovative therapeutic approach built on promising clinical data.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing